Creative Biolabs has been a long-term expert in psychotropic drug development that offers a full range of psychotropic drug development services. With years of study, the advanced platforms at Creative Biolabs have the potential to discern new drug targets and accelerate drug discovery and personalized medicine for psychiatric disorders.
Psychotropic Drug Development
Psychiatric disorders, such as depression, anxiety, and schizophrenia, are the leading causes of disability worldwide. There is an urgent need for new treatments and new drugs to treat psychiatric disorders. While progress in developing fundamentally new approaches to treating psychiatric disorders over the past several decades has been slow, evaluation of the current landscape of drug discovery in this arena is very encouraging. The complex etiology, subjective diagnosis of mental disorders, and idiosyncratic responses to pharmacotherapy help discover new drugs to treat psychiatric disorders highly challenging. Our seasoned scientists have currently set up a series of one-stop procedures to assist your psychotropic drug development with the highest efficiency and the best quality to overcome all these challenges.
Our knowledge from omics studies, in conjunction with a detailed understanding of imaging, even the technology of provocative anxiety tests, will help establish a psychiatric disease research platform for our customers worldwide. With our extensive experience and advanced platform, we are confident in offering the best research tools for psychiatric disease research.
In the development of psychiatric drugs, the transportation of CNS is one of the critical issues. Creative Biolabs offers a series of systematic analyses of CNS transport, which will provide a basis for developing more effective psychiatric drugs. These systematic analyses involve CNS transport from phenomenology, CNS transport from physiology/pharmacology, CNS transport from biochemical pharmacology, anatomy and histology, and CNS transport from molecular biology.
To predict or monitor treatment responses more precisely, biomarkers will need to characterize the patient’s condition in an integrated manner. A wide variety of biomarkers currently are being investigated in psychiatry and neurology encompass. Some biomarkers for the future development of psychopharmaceutical drugs have been used for antidepressants, anxiolytics, and antipsychotics. Our expertise in complex biomarkers development can give you a detailed insight into your biologic, helping to not only accelerate your drug development process but also elucidate underlying pathophysiology, further, to serve these biomarkers as diagnostic tools or predicting treatment responses.
Primary psychiatric drug targets have been linked to the risk of disease at the population level through large-scale studies, including the monoamine transporters antagonists, hypothalamic-pituitary-adrenal (HPA) axis antagonists, glutamate receptors, and cannabinoid receptor antagonists. Besides, the growing evidence that action at multiple targets is required for the full efficacy of many of the most successful drugs makes it imperative that we focus on developing new approaches for the rational design of targets. Together, the target development platform at Creative Biolabs provides a novel paradigm for performing pharmacological studies and drug discovery for psychiatric disorders.
The development of an animal model for psychiatric disorders is particularly challenging because of its nature. The development of the most effective therapeutic agents in psychiatry will depend on testing in an appropriate preclinical model, in which the drugs would be capable of acting on the primary site of the pathology. This could be achieved by engineering new preclinical models made up of animals carrying a genetic vulnerability (such as a gene dosage) with a good face, construct, and predictive validity, interfaced with validated stress paradigms. Such interchange between basic preclinical models and human pathophysiology can refine the understanding of complex psychiatric disorders.
The entire drug discovery and development process in psychiatric disorders involves one of the target validation methods in many ways. The ultimate validation of the target also occurs when the drug is widely prescribed on the market. Creative Biolabs focuses significant effort on continually validating and qualifying a target at every step in the process for our customers' projects. Technological advances have enabled our knowledge of psychotropic drugs' biochemical targets, facilitating a rational design strategy to refine their therapeutic effects while reducing side effects, and improving safety and tolerability.
Based on our advanced platform, Creative Biolabs provides you with comprehensive psychotropic drug development. Furthermore, our psychotropic disorder research experience and our drug development background make us an excellent choice for our global customers. We would be pleased to provide support for any of your questions. Please ask an expert for a specific consultation on your project.
For Research Use Only.
